Jatcorp Limited Overview
Jatcorp is a micro-cap Australian health-and-wellness dairy nutrition company whose identity rests on two assets. The first is a portfolio of lactoferrin-fortified formulated milk powders sold under the Neurio® and Moroka® brands, aimed mainly at Chinese consumers seeking immunity products. The second is the ANMA powder-blending and canning facility in Derrimut, Melbourne, which supports both its own brands and higher-margin OEM contract manufacturing for third parties. In FY2026 it generated A$38.9m revenue (+23%), a A$6.1m audited gross profit and a A$4.7m statutory net loss. Its auditor has flagged a going-concern material uncertainty. Roughly three-quarters of revenue is booked in its Australian segment, much of it with a single customer and likely destined for Chinese cross-border channels. Its largest shareholder (31.3%) is also its exclusive China distributor. The equity story is a turnaround: shrinking the cost base, rebuilding Neurio after a Chinese trademark loss, and growing OEM and Southeast Asian revenue.
Company's own description (paraphrased from 1H FY26 Interim Report, Directors' Report "Principal activities")
The company describes itself as an innovation-led producer of dairy and nutrient products in Australia serving Asia-Pacific markets. Its activities fall into two strands.
The first strand is innovation and new product development. This means manufacturing a range of consumer formulations for every age group from infants to seniors. The formulations frequently incorporate lactoferrin, which the company positions as supporting immune function, intestinal health and related benefits.
The second strand is brand development. This centres on the flagship brands Neurio® and Moroka®. It covers marketing and promotion and the sale of both proprietary and client products. Distribution is multi-channel, spanning traditional retail and e-commerce, with Australia and China as the primary markets.
In ASX boilerplate, the company calls itself a leading producer of supplementary food and plant-based products (CEO appointment announcement, 15 September 2025).
Independent characterisation
Jatcorp is best understood as a small vertically integrated nutritional-powder brand owner and contract manufacturer whose end-demand is overwhelmingly Chinese. It does not farm milk or produce lactoferrin; it buys dairy bases and functional ingredients, then blends, cans and packs them at ANMA. It sells its own brands to distributors and e-commerce operators, and sells manufacturing capacity to other brand owners on an OEM basis.
Value-chain position
-
Upstream: purchased milk powders, lactoferrin, IgG, vitamins and minerals, and packaging (raw materials A$2.22m and packaging A$1.19m of inventory at 30 June 2026).
-
Midstream: blending and canning at ANMA.
-
Downstream: sale to distributors and cross-border e-commerce (CBEC) operators, principally the HS Group (HS Global E-Commerce (HK) Limited / "H&S International"), plus Australian, New Zealand, Hong Kong and Vietnamese channels.
Revenue model
-
100% of FY2026 revenue is "goods transferred at a point in time" (FY2026 Preliminary Financial Report, Note 4). There is no subscription, licensing or service revenue line.
-
The mix splits between own-brand product sales (Neurio, Moroka, Jinvigorate and others) and OEM manufacturing revenue (e.g., BTNature, a Taiwan client, and the new India-bound customer).
-
The precise branded-versus-OEM split is not publicly disclosed.
Commercial structure worth noting
-
Large customer prepayments (contract liabilities of A$4.22m at 30 June 2026). Customers paid A$18.94m in advance during FY2026 (Note 10).
-
A trade promotion expense (TPE) payable to the HS distributor as a fixed percentage of sales. From FY2026 this is netted against revenue (Note 2).
-
A share-based sales incentive plan with a distributor (1,000,000 shares issued 2 September 2025).
Customer types
-
Distributors and wholesale partners (largest category). One Australian-segment customer contributed A$23.64m (60.8%) of FY2026 revenue, and one China-segment customer A$5.03m (12.9%) (Note 3, Major customers).
-
E-commerce platforms. Historic flagship stores on Tmall Global, JD Worldwide/JD Global and Pinduoduo were operated before the company terminated its own China online store operations in Q4 FY2026 (Kalkine summary of Q4 FY26 4C).
-
Bricks-and-mortar mother-and-baby stores in China (Moroka in approximately 150 stores, 1H FY26), plus stores in Hong Kong and Vietnam.
-
OEM brand-owner customers using ANMA capacity.
End-markets served
-
Paediatric and maternal nutrition (formulated milk powders for children).
-
Adult and senior immunity and wellness powders.
-
Medical-adjacent nutrition (Jinvigorate Diabetic Formula, low-GI certified).
-
OEM nutritional powders for third-party brands.
Strategy
Stated strategy themes (latest filings; paraphrased)
-
Brand-led growth with OEM support. In 2024 management announced a pivot away from a distribution and OEM model towards its own brands, with OEM manufacturing taking a supporting role (FoodNavigator-Asia, Sept 2024). By FY2026 the emphasis had rebalanced: management now describes higher-margin OEM manufacturing at ANMA as a key priority alongside Moroka brand expansion (1H FY26 Interim Report outlook).
-
Dual-brand lactoferrin strategy. A "double-brand strategy" around lactoferrin products (1H FY24 Interim Report), now Neurio plus Moroka.
-
"New channels" in China. Moving beyond pure e-commerce into mother-and-baby retail (about 150 stores in 1H FY26). This culminated in a new cooperation model with HS as exclusive China distributor and the termination of company-run online stores (Q4 FY26).
-
Southeast Asian diversification. Vietnam exclusive distributor (signed 1H FY26); Malaysia and Indonesia discussions under way.
-
Manufacturing capability. Infrastructure upgrades and automation at ANMA; capacity doubled in 1H FY26; next upgrade phase in preparation.
-
Cost discipline. Every expenditure category fell in Q4 FY26: manufacturing and operating costs −20%, advertising −57%, administration −19% (Q4 FY26 4C).
-
Inorganic optionality. Management said in 2024 that it was looking for Australian health and nutrition brands to acquire (FoodNavigator-Asia). No transaction has been announced since.
-
Risk management priorities. Four stated focus areas: protecting trademarks and IP, diversifying the customer base through portfolio expansion, entering new markets, and retaining talent (1H FY26 Interim Report).
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Detail | Target / status |
|---|---|---|---|
| H&S International sales incentive deed (Moroka) | Feb 2025 | Incentive arrangement to drive Moroka purchases in mainland China | A$11m FY2026 Moroka purchase target. Actual FY2026 China-segment revenue was A$7.97m, though HS purchases may be booked in other segments (not disclosed) |
| Sales incentive plan share issue | 2 Sep 2025 | 1,000,000 shares issued to a distributor (A$280k at A$0.28 per the interim report; A$442k per the FY2026 accounts, a discrepancy) | Completed |
| HQ consolidation to Derrimut | Jul 2025 | Registered office moved to the ANMA site | Completed |
| Non-core property sale | Oct–Nov 2025 | A$1.10m sale | Completed |
| Vietnam exclusive distribution agreement | 1H FY26 | Products developed specifically for Vietnam | Launched; A$0.37m FY2026 revenue |
| BTNature manufacturing arrangement | 1H FY26 | OEM production commenced | Ongoing |
| ANMA production line upgrade | 1H FY26 | Doubled capacity | Completed; next phase planned |
| China retail expansion | 1H FY26 | Moroka into about 150 mother-and-baby stores | Ongoing |
| CIIE Shanghai participation | Nov 2025 | Showcased manufacturing; prospective customers then visited ANMA | Completed |
| A$4.2m entitlement offer | Dec 2025 – Jan 2026 | Fully underwritten by HS Global E-Commerce (HK) | Completed 16 Jan 2026 |
| China distribution model reset | Q4 FY26 | New cooperation model with H&S as exclusive China distributor; termination of company-run online stores | Under execution |
| India-bound OEM customer | Q4 FY26 | ANMA's first OEM customer selling into India | Commenced |
| Malaysia and Indonesia distribution | Q4 FY26 | Distributor discussions progressing | Pending |
| R&D | FY2026 outlook | Targeted R&D to support innovation in branded and OEM offerings | No spend disclosed |
ESG / sustainability commitments
None disclosed. The company will first become subject to mandatory climate reporting (AASB S2) potentially for the year ending 30 June 2028 (1H FY26 Interim Report).
Medium-term targets and guidance
No quantitative medium-term revenue, margin or EBITDA targets have been issued. The only quantified commercial target located is the A$11m FY2026 Moroka purchase target under the HS deed. The going-concern note refers to a cash-flow forecast "assuming that project profits are met", but the projections are not disclosed.
Products & Services
Jatcorp has no product segments, so products are organised by brand and channel. Pricing is not publicly disclosed for any product.
Own brands — functional dairy (core)
| Brand / product | Owner entity | Description and key specifications | Target customer | Launch / latest year | Notes |
|---|---|---|---|---|---|
| Neurio® Formulated Milk Powder with Lactoferrin | Sunnya Pty Ltd (51%) | Lactoferrin formulated milk powder with sialic acid, zinc, iron and calcium (FoodNavigator-Asia, Sept 2024) | Children through adults; immunity-focused Chinese consumers | Brand predates JAT's 2018 Sunnya acquisition; relaunched in China CBEC FY2024 | Flagship. China online sales suspended after the adverse trademark ruling (FY2025). Sold via retail outlets in China, plus Australia and Hong Kong, where demand rose in 2Q FY26 (1H FY26 Interim Report). Inventory impairment provision A$0.66m at 30 June 2026 (FY2026 Note 8) |
| Neurio DHA Algae Oil Softgel and other Neurio SKUs | Sunnya | DHA algae oil softgels and lactoferrin powders listed in the 2018 portfolio | Maternal / child | 2018 or earlier | Current availability not confirmed |
| Moroka® Platinum Formulated Milk Powder with Lactoferrin + IgG | Jatcorp group | Lactoferrin plus immunoglobulin G, with vitamins A, D, B6, C, E, zinc, selenium and iron (FoodNavigator-Asia) | Young children to seniors | Brand launched 28 June 2023 (Shanghai CBME) | Second flagship. Principal China driver in FY2025–26 under the HS/H&S incentive deed (A$11m FY26 purchase target). In about 150 Chinese mother-and-baby stores (1H FY26). Two new Moroka products launched in Q1 FY25 (Inside FMCG). Australian rollout accelerated in Q4 FY26 |
| Moroka branded lactoferrin (stand-alone) | Jatcorp group | Lactoferrin product launched at the 2023 Shanghai Expo | Immunity consumers | 2,023 | Tmall flagship established in 2023 |
| "Morokal®" | Jatcorp group | Referred to in the FY2026 Appendix 4E commentary as continuing to grow in China | China consumers | — | Possibly a variant name of Moroka; not separately described |
| Vietnam-specific products | Jatcorp group | Products developed specifically for Vietnam under an exclusive distribution agreement | Vietnamese consumers | Launch targeted before end of FY2026 | Vietnam revenue A$0.37m in FY2026 |
Own brands — specialised nutrition
| Brand / product | Description | Target customer | Year | Notes |
|---|---|---|---|---|
| Jinvigorate Diabetic Formula | Milk formula for diabetes market; analysed by the University of Sydney; granted Low GI Symbol Certification by the Australian Glycemic Index Foundation; manufactured at ANMA (Just Food) | People managing blood glucose | Announced c.2019–2020 | Morningstar lists Jinvigorate among current brands |
| Diabetic supplement powder and Immune supplement powder (Taiwan client) | First order of over 13,000 units delivered in June 2023 | Taiwan market | 2,023 | Opened Taiwan market (FY2023 Appendix 4E) |
| iOne | Listed among company brands (Morningstar; Simply Wall St) | — | — | Product details not publicly disclosed |
| Goat milk powder-based products / children's goat milk powder | ANMA's first Taiwan orders were for children's goat milk powder (Just Food) | Children | c.2019–2020 | — |
| Cow milk powder, cream and skim milk powders | Listed in company description (Simply Wall St) | B2B / consumer | Ongoing | — |
Other and legacy brands
| Brand | Description | Status |
|---|---|---|
| Abbeyard | Listed brand (IBISWorld) | Details not disclosed |
| Poupin | Listed brand (IBISWorld) | Details not disclosed |
| V Meat | Listed brand (IBISWorld); consistent with the company's "plant-based" descriptor | Details not disclosed |
| Cobbity Country | Oats and FMCG brand developed with Shanghai Dragon (2018) | Entity Cobbity Country Pty Ltd remains 100% owned; current activity not disclosed |
| Golden Koala | Infant formula including O-P-O premium infant formula and full-cream milk powder (2018 presentation) | Entity deregistered 3 February 2026 |
| Green Forest distributed brands (third-party, e.g. Blackmores, Swisse, a2, Aptamil, Bellamy's, Thermos, Camelbak) | Daigou wholesale and distribution | Exited with Green Forest disposal, 9 March 2023 |
Services — OEM / contract manufacturing at ANMA
| Service | Description | Named customers / evidence | Year |
|---|---|---|---|
| OEM powder blending and canning | Contract manufacturing of formulated milk powders for third-party brand owners | BTNature: up to about A$28m contract (Oct 2022); new manufacturing arrangement in 1H FY26 with initial orders received | 2022–2026 |
| — | — | Taiwan client (2023) | 2,023 |
| — | — | Two new customers in Q4 FY26, including the first customer manufacturing for sale in India; existing customers transferred orders from other manufacturers to ANMA (Q4 FY26 4C) | 2,026 |
| Capacity | A major production line upgrade in 1H FY26 doubled production capacity; next phase of technology and line upgrades in preparation (1H FY26 Interim Report; Q4 FY26 4C) | — | 2025–2026 |
Financial Narrative
Basis of preparation and data-quality warnings
-
FY2026 and FY2025 use the audited FY2026 Annual Report basis. This includes (a) the TPE restatement that reduced FY2025 revenue by A$3.29m and (b) the reclassification of manufacturing labour and depreciation into COGS: A$1.98m in FY2026 and A$1.94m in FY2025.
-
FY2024 figures come from secondary summaries of the FY2024 Annual Report: continuing revenue A$52.4–52.5m, net profit A$1.6m, total assets A$25.36m, total equity A$10.83m, operating cash flow A$2.82m, and adjusted EBITDA A$3.7m. A full FY2024 income statement was not located.
-
FY2023 uses the FY2023 Appendix 4E as reported, with A$57.37m continuing revenue including the A$20m Hong Kong trading business. The FY2024 report later appears to have re-presented FY2023 continuing revenue at about A$37m: A$52.5m is stated as +42%, implying about A$37m. The two FY2023 bases conflict.
-
FY2022 uses the FY2023 Appendix 4E comparatives (revenue A$34.14m). The FY2022 Appendix 4E originally reported revenue of A$37.86m, before Green Forest was classified as discontinued.
-
Pre-FY2024 per-share data are on a pre-consolidation basis (implied 1-for-30 consolidation in FY2024).
Income statement
Notes to the income statement table
-
FY2024 attributable profit of A$2.22m is implied from the movement in accumulated losses: A$81.95m at 30 June 2023 to A$79.73m at 1 July 2024. It is not a reported figure.
-
FY2024 adjusted EBITDA of +A$3.7m comes from the InvestSMART summary of the FY2025 Annual Report.
-
FY2025 adjusted EBITDA is stated as −A$1.8m in the FY2026 results commentary and −A$1.7m in the FY2025 report summary. This is a minor discrepancy.
-
D&A shown is the pre-reclassification total. After the audit reclassification, D&A in operating expenses is A$0.25m (FY2026) and A$0.32m (FY2025), with the remainder moved into COGS.
-
FY2022 and FY2023 COGS include inventory write-downs of A$3.50m and A$1.04m. FY2025 and FY2026 COGS include write-downs of A$1.46m and A$0.66m.
-
FY2026 operating expenses also include a A$0.70m loss on deconsolidation of a subsidiary.
Margins and growth (%; analyst-derived)
How the growth and margin figures are computed
-
FY2022 growth is measured against FY2021 reported revenue of A$20.96m.
-
FY2024 growth is measured against FY2023 as reported (A$57.37m). Against the re-presented FY2023 continuing base of about A$37m, FY2024 growth was about +42%.
-
FY2025 growth uses restated FY2025 revenue (A$31.55m) against A$52.45m. On the originally reported A$34.84m, the decline was about 34%.
Revenue CAGR
-
FY2022 to FY2026: 3.3% per year, using A$34.14m as the base.
-
FY2021 to FY2026: 13.2% per year, using A$20.96m as the base.
Commentary — revenue. Revenue has been volatile because the business model has changed repeatedly. FY2023's A$57.4m was inflated by the BTNature OEM contract and A$20m of Hong Kong international trading. FY2024's A$52.5m continuing revenue reflected the lactoferrin brand boom in China; China then represented over 80% of revenue according to the CEO (FoodNavigator-Asia, Sept 2024). FY2025 fell sharply on two causes: the deliberate exit from low-margin trading and the unexpected suspension of Neurio sales in China (Just Food; Inside FMCG). FY2026 recovered 23%, driven by Neurio demand in Australia and Hong Kong, Moroka in China, OEM orders and Vietnam.
Commentary — margins. On the audited basis, gross margin compressed from 19.8% to 15.8% in FY2026 despite higher revenue. Absolute gross profit was flat at about A$6.1–6.2m. The 1H FY26 gross margin was 30.0%, but that was on the pre-reclassification basis and before the FY2026 TPE netting.
The decline suggests three things:
-
second-half mix shifted towards lower-margin OEM work and Australian distributor sales;
-
TPE netting depresses reported revenue per unit;
-
inventory write-downs persisted (A$0.66m).
Commentary — profitability. Operating losses narrowed in FY2026 mainly because:
-
consultancy and professional fees fell from A$4.11m to A$2.61m as China legal spending moderated;
-
impairments normalised from A$2.64m to A$0.06m;
-
advertising fell from A$3.05m to A$2.61m.
Administration expenses rose from A$1.44m to A$1.91m.
The attributable loss nonetheless widened, from A$2.47m to A$3.49m. The FY2025 loss had been disproportionately absorbed by the 49% minority in Sunnya: the NCI share was A$4.47m of the A$6.93m loss.
Balance sheet
Notes to the balance sheet table
-
FY2024 total liabilities are derived as total assets less total equity. FY2024 owners' equity is derived from the 1 July 2024 equity balances in the FY2025/FY2026 statement of changes in equity.
-
FY2025 receivables are shown on the FY2026 presentation, which separates prepayments to suppliers (A$2.28m). The 1H FY26 report showed FY2025 current receivables of A$4.56m including supplier deposits.
-
Net debt is shown as negative when the group holds net cash.
Commentary. The balance sheet is small and lightly geared on bank debt. Borrowings are almost entirely A$1.39m of interest-free, unsecured shareholder loans with no fixed repayment terms. The A$3m bank facility (A$2m overseas bills purchased, 60-day; A$1m trade refinance, 120-day) was undrawn at reporting dates and is available until 30 July 2027 (FY2026 going-concern note).
The main balance-sheet risks are:
-
lease liabilities of A$5.17m, principally for the Derrimut premises;
-
customer prepayments of A$4.22m, which represent delivery obligations rather than cash debt;
-
erosion of total equity, which fell from A$10.83m (FY2024) to A$4.63m (FY2026).
Goodwill and intangibles are now negligible (A$0.09m) after the FY2025 write-off of Sunnya goodwill. The NCI balance has turned negative (−A$2.61m) because minority partners' share of accumulated Sunnya and LTVM losses exceeds their capital.
Cash flow
Notes to the cash flow table
-
The FY2023 cash flow statement shows "payments for PP&E" as a positive A$235,285 against PP&E additions of A$229,283. This is likely a sign-presentation error in the unaudited 4E, so the absolute value is used here.
-
FY2026 proceeds from asset disposals relate to the property held for sale, sold for A$1.10m.
-
The FY2025 share issue was A$234 on the exercise of options, shown as 0.
Commentary. Cash generation is weak and episodic. FY2024 (+A$2.82m) and FY2025 (+A$1.63m) were positive, but FY2025 was flattered by working capital. FY2026 reverted to a −A$1.36m operating outflow despite better earnings, driven by the unwinding of trade payables, which fell from A$6.99m to A$4.26m, including the settlement of Neurio refund liabilities.
Year-end cash of A$5.61m was achieved only through the A$4.13m net entitlement offer and the A$1.08m property sale. Q4 FY26 alone produced a +A$0.92m operating inflow on a much-reduced cost base (Q4 FY26 4C). The company has needed equity in three of the last five years.
Ratios (analyst-derived)
Ratios that cannot be meaningfully calculated
ROIC: not meaningful, as NOPAT is negative in four of five years.
Net debt/EBITDA and interest coverage: not meaningful, as EBITDA is negative except FY2024 adjusted. Group finance costs were A$0.32m in FY2026, of which A$0.32m is lease interest.
Cash conversion cycle (approximate)
-
FY2026: about 50 days (DSO 21 + DIO 35 − DPO 6).
-
FY2025: about 60 days (DSO 26 + DIO 69 − DPO 35).
-
Both are derived using trade payables only. They are distorted by large customer prepayments, which effectively make the working-capital cycle partly customer-financed.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue, continuing (AUD Mn) | 34.14 | 57.37 | 52.45 | 31.55 | 38.87 |
Cost of goods sold (AUD Mn) | 30.14 | 46.13 | — | 25.31 | 32.72 |
Gross profit (AUD Mn) | 4.00 | 11.24 | — | 6.24 | 6.15 |
EBITDA, statutory (AUD Mn) | -7.70 | -3.90 | — | -5.86 | -3.37 |
Adjusted EBITDA (AUD Mn) | -6.46 | -3.28 | 3.70 | -1.80 | -2.70 |
Depreciation & amortisation, total (AUD Mn) | 1.01 | 1.02 | — | 1.09 | 1.06 |
EBIT, derived (AUD Mn) | -8.71 | -4.92 | — | -6.95 | -4.43 |
Finance costs (AUD Mn) | 1.17 | 0.19 | — | 0.36 | 0.32 |
Impairment losses (AUD Mn) | 1.24 | 0.74 | — | 2.64 | 0.06 |
Profit before tax, continuing (AUD Mn) | -8.47 | -2.66 | — | -7.29 | -4.77 |
Net profit after tax, total incl. discontinued (AUD Mn) | -10.01 | -4.61 | 1.60 | -6.93 | -4.69 |
Net profit attributable to owners (AUD Mn) | -6.97 | -4.48 | 2.22 | -2.47 | -3.49 |
Non-controlling interest share of result (AUD Mn) | -3.04 | -0.14 | — | -4.47 | -1.20 |
Basic EPS, as reported (AUD cents) | -0.37 | -0.18 | — | -2.96 | -3.60 |
Basic EPS, consolidation-adjusted ×30, derived (AUD cents) | -11.10 | -5.40 | — | -2.96 | -3.60 |
Diluted EPS, as reported (AUD cents) | -0.37 | -0.18 | — | -2.96 | -3.60 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 62.9 | 68.0 | -8.6 | -39.8 | 23.2 |
Gross margin, audited basis (%) | 11.7 | 19.6 | — | 19.8 | 15.8 |
Gross margin, pre-reclassification basis (%) | 11.7 | 19.6 | — | 25.9 | 20.9 |
EBITDA margin, statutory (%) | -22.6 | -6.8 | — | -18.6 | -8.7 |
Adjusted EBITDA margin (%) | -18.9 | -5.7 | 7.1 | -5.7 | -6.9 |
Net margin, total (%) | -29.3 | -8.0 | 3.1 | -22.0 | -12.1 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | 22.80 | 26.31 | 25.36 | 22.62 | 20.43 |
Cash and equivalents (AUD Mn) | 3.86 | 3.81 | 2.47 | 2.72 | 5.61 |
Trade and other receivables, current (AUD Mn) | 1.84 | 7.27 | — | 2.28 | 2.28 |
Inventories (AUD Mn) | 4.95 | 4.73 | — | 4.81 | 3.12 |
Property, plant & equipment (AUD Mn) | 5.10 | 4.85 | — | 3.62 | 3.68 |
Right-of-use assets (AUD Mn) | 3.53 | 2.49 | — | 5.02 | 4.79 |
Goodwill and intangibles (AUD Mn) | 2.96 | 2.71 | — | 0.09 | 0.09 |
Borrowings, current (AUD Mn) | 1.78 | 3.17 | — | 1.39 | 1.39 |
Borrowings, non-current (AUD Mn) | 1.60 | 0 | — | 0 | 0 |
Total borrowings excl. leases (AUD Mn) | 3.39 | 3.17 | — | 1.39 | 1.39 |
Lease liabilities, total (AUD Mn) | 4.03 | 2.76 | — | 5.23 | 5.17 |
Net debt excl. leases (AUD Mn) | -0.47 | -0.63 | — | -1.32 | -4.22 |
Net debt incl. leases (AUD Mn) | 3.56 | 2.13 | — | 3.91 | 0.95 |
Contract liabilities, customer prepayments (AUD Mn) | 3.70 | 7.58 | — | 4.44 | 4.22 |
Total liabilities (AUD Mn) | 15.32 | 15.87 | 14.53 | 18.64 | 15.80 |
Equity attributable to owners (AUD Mn) | 6.84 | 8.28 | 8.17 | 6.08 | 7.24 |
Non-controlling interests (AUD Mn) | 0.64 | 2.16 | 2.66 | -2.10 | -2.61 |
Total equity (AUD Mn) | 7.48 | 10.44 | 10.83 | 3.98 | 4.63 |
Working capital, current assets less current liabilities (AUD Mn) | 1.14 | 2.63 | — | -0.08 | 0.74 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | -2.78 | -0.96 | 2.82 | 1.63 | -1.36 |
Capex, payments for PP&E (AUD Mn) | 1.38 | 0.24 | — | 0.42 | 0.45 |
Free cash flow, OCF less capex (AUD Mn) | -4.17 | -1.20 | — | 1.21 | -1.82 |
Proceeds from share issues, net (AUD Mn) | 8.04 | 4.25 | 0 | 0 | 4.13 |
Dividends paid to ordinary shareholders (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Dividends paid by subsidiaries to minorities (AUD Mn) | 1.18 | 0 | — | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Lease principal repayments (AUD Mn) | 0.42 | 0.55 | — | 0.47 | 0.50 |
Proceeds from asset disposals (AUD Mn) | 0 | 0 | — | 0 | 1.08 |
Net change in cash (AUD Mn) | -2.55 | -0.05 | — | 0.25 | 2.89 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE, total result / average total equity (%) | -115.1 | -51.5 | 15.0 | -93.6 | -108.9 |
ROA, total result / closing total assets (%) | -43.9 | -17.5 | 6.3 | -30.7 | -22.9 |
Current ratio (x) | 1.12 | 1.20 | — | 0.99 | 1.07 |
Debt/equity, borrowings excl. leases (x) | 0.45 | 0.30 | — | 0.35 | 0.30 |
Debt/equity, incl. leases (x) | 0.99 | 0.57 | — | 1.66 | 1.42 |
Asset turnover, revenue / closing assets (x) | 1.50 | 2.18 | 2.07 | 1.40 | 1.90 |
Days inventory outstanding (days) | 60 | 37 | — | 69 | 35 |
Revenue by Region
| Region | FY2025 | FY2026 |
|---|---|---|
Australia (AUD Mn) | 22.08 | 30.13 |
China (AUD Mn) | 9.19 | 7.97 |
New Zealand (AUD Mn) | 0.29 | 0.40 |
Vietnam (AUD Mn) | 0 | 0.37 |
Region Overview
| Region | FY2026 |
|---|---|
Australia growth (%) | 36.5 |
China growth (%) | -13.3 |
New Zealand growth (%) | 41.2 |
Revenue by Region and Revenue by Region (%)
| Region | FY2022 | FY2023 |
|---|---|---|
International revenue (AUD Mn) | 8.77 | 24.20 |
Domestic (Australia) revenue (AUD Mn) | 25.37 | 33.17 |
International share of revenue (%) | 25.7 | 42.2 |
Observation Details
| Observation | Price (AUD) | Source / date |
|---|---|---|
Price at release of Q4 FY25 4C | 0.37 | InvestSMART, 30 Jul 2025 |
Price at release of FY2025 results | 0.32 | InvestSMART, 29 Aug 2025 |
Entitlement offer issue price | 0.15 | 16 Jan 2026 |
Mid-2026 aggregator quotes | 0.11–0.14 | InvestSMART; Simply Wall St; TradingView |
Latest observed | 0.086 | Listcorp (Iress), viewed Oct 2026 |
Share Price & Returns
| Horizon | Return % | Basis |
|---|---|---|
1-year | -73 | A$0.32 (29 Aug 2025) to A$0.086 (Oct 2026), analyst-derived. TradingView showed −59.7% for one year at A$0.13 |
Share Count (M)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Shares on issue, as reported (M) | 2,141.10 | 2,497.95 | 83.27 | 83.27 | 112.36 |
Shares, post-consolidation equivalent ÷30, derived (M) | 71.37 | 83.27 | 83.27 | 83.27 | 112.36 |
Capital Markets
| Metric | Jatcorp |
|---|---|
Market capitalisation | A$9.66m |
Enterprise value excl. leases | A$5.44m |
Enterprise value incl. leases | A$10.61m |
EV/Sales excl. leases | 0.14x |
EV/Sales incl. leases | 0.27x |
P/E | Not meaningful (loss-making) |
EV/EBITDA | Not meaningful (negative EBITDA) |
P/B on owners' equity (A$7.24m) | 1.33x |
Price / NTA (4.048c) | 2.1x |
Capital Instruments
| Instrument | Amount (AUD Mn) | Terms |
|---|---|---|
Shareholder loans | 1.39 | Unsecured, interest-free, no fixed repayment terms |
Lease liabilities, current | 0.50 | Due within 12 months |
Lease liabilities, non-current | 4.67 | Leases of 3–10 years |
Bank trade facilities, undrawn | 3.00 | A$2m 60-day plus A$1m 120-day drawings; available to 30 Jul 2027 |
Revolving leasing limit, undrawn | 1.50 | Per 1H FY26 Note 14 |
Analyst Conclusions
Management guidance
No numeric FY2027 guidance has been issued. Qualitative priorities from the 1H FY26 outlook and Q4 FY26 commentary are:
-
continued revenue growth through distribution partners in Southeast Asia;
-
Moroka expansion;
-
execution of the new HS exclusive China distribution model;
-
the next phase of ANMA upgrades;
-
higher-margin OEM growth;
-
targeted R&D.
The going-concern assessment relies on a cash-flow forecast assuming "project profits are met", on access to the A$3m facility, and on the ability to cut discretionary consultancy spending.
Consensus growth expectations
Not available (no analyst coverage).
Bull case
-
Operating inflection is visible. Q4 FY26 delivered +12% revenue and +A$0.92m operating cash flow on a cost base cut across every category. If sustained, a full-year run-rate around cash breakeven is plausible on about A$40m+ revenue.
-
OEM optionality on a doubled ANMA. New customers (including India-bound) and order transfers from rival manufacturers could raise utilisation and absorb fixed costs. The audited COGS now carries about A$2m of manufacturing labour and depreciation.
-
Neurio IP recovery and strategic backing. A favourable trademark invalidation outcome would reopen the China CBEC channel that drove FY2024's A$52.5m revenue and A$1.6m profit. A 31% shareholder who is also the distributor has incentives to drive volume. At about 0.14–0.27x EV/Sales, the market prices in little recovery.
Bear case
-
Structural margin problem. The audited gross margin fell to 15.8% in FY2026 even as revenue grew. At under half of Bubs' gross margin, there is little room to fund marketing, R&D and listed-company costs.
-
Control and concentration. The top two customers account for about 74% of revenue, and HS is shareholder, exclusive distributor, TPE recipient and underwriter. Minority shareholders bear counterparty and pricing risk with limited board independence to police it.
-
Credibility and funding risk. Successive restatements and reclassifications, persistent going-concern qualifications, and three capital raisings in five years point to continued dilution and a governance discount. The 73% one-year share price fall suggests the market already sees this.
Key catalysts and monitorables (next 12 months)
| Expected timing | Catalyst |
|---|---|
| Late Oct 2026 | Q1 FY27 Appendix 4C: is cash flow holding positive after the seasonal Q1 lull? |
| Around Nov 2026 | AGM (date not yet confirmed in sources reviewed): remuneration vote, director elections, any strategy update |
| Ongoing | Neurio China trademark invalidation rulings; Niurui/GABT compensation enforcement |
| Ongoing | Quantification of the new HS cooperation model; FY2027 volume commitments |
| Ongoing | Named OEM contracts at ANMA; utilisation; next-phase upgrade capex |
| Ongoing | Malaysia and Indonesia distributor agreements; Vietnam sell-through |
| Late Feb 2027 | 1H FY27 results: audited-basis gross margin trend; going-concern status |
| Ongoing | Any new capital raising or related-party transaction requiring shareholder approval |
| Ongoing | NSW indemnity cost assessment outcome (cash recovery) |
Concluding analyst verdict
Jatcorp is a sub-A$10m-capitalisation turnaround whose investment case rests on a single strategic asset and a single strategic relationship. The asset is a China-capable powder plant in Derrimut whose capacity has just been doubled. The relationship is with the HS Group, now a 31% shareholder and exclusive China distributor.
FY2026 delivered progress. Revenue grew 23% to A$38.9m, the statutory loss narrowed 32% to A$4.7m, impairments normalised and legal costs fell. The fourth quarter was cash-generative. Cash ended at A$5.6m with no interest-bearing bank debt.
The quality of that progress is questionable, however. Audited gross profit was flat at about A$6.1m and the audited gross margin fell to 15.8%. Operating cash flow for the year was negative, and the attributable loss to Jatcorp shareholders widened to A$3.5m. In the space of a month the company corrected an AASB 15 error and accepted an audit reclassification. The auditor again flagged a going-concern material uncertainty. Two customers account for roughly three-quarters of revenue, and the board has only one expressly independent director while related-party flows with the controlling distributor are growing.
On balance this is a high-risk, binary micro-cap. Upside depends on three outcomes:
-
OEM utilisation lifting margins towards the 25–30% achieved before the cost reclassification;
-
HS converting exclusivity into contracted, growing volumes;
-
Chinese courts restoring Neurio's trademark position.
Downside is continued margin dilution, further equity issuance on HS-friendly terms and minority value leakage. The valuation of about 1.3x book and 0.1–0.3x EV/Sales offers optionality, not protection.
Investors should require two consecutive cash-positive quarters on the audited cost basis, disclosure of HS contract economics and strengthened board independence before treating the turnaround as established. Until then the stock suits only speculative mandates able to absorb a total loss.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Background / prior roles | Education |
|---|---|---|---|---|
Peng Shen | Non-Executive Chairman | Director since 20 Jun 2022; Chairman since 1 Sep 2022 | Former CFO of Yancoal Australia (to 2013); Secretary and Director at China Shenhua Energy; Director of Investor Relations at CHN Energy Investment Group; former director of Carabella Resources and Wanguo Gold Group; senior auditor at Deloitte Touche Tohmatsu (MarketScreener) | University of Melbourne (graduate, 2003); Central University of Finance & Economics (undergraduate, 1998) |
Dr Xinpeng (Sean) Li | Executive Director and CEO | ED since Mar 2025; acting CEO from 3 Sep 2025; CEO since 15 Sep 2025 | 10+ years in commercialisation, investment analysis, operations and cross-border acquisitions; senior roles at Power Construction Corporation of China (ASX announcement, 15 Sep 2025) | BEng Chemical Engineering (Northwest University); Master of Mechanical Engineering (UNSW); PhD Chemistry (UNSW) |
Kieran Pryke | Non-Executive Independent Director | Appointed c.2024 | More than two decades of financial expertise (Motley Fool profile) | — |
Zhan (Jack) Wang | Non-Executive Director | Re-appointed 29 Oct 2025 | ED from Jun 2022; MD Sep 2022 to Nov 2024; sole director of Gold Brick Capital (19.99% holder at Nov 2024); director of Pacific Healthy International Holdings and Pacific Healthy ANZ (distributors of dairy products, vitamins and cosmetics); more than a decade in cross-border e-commerce (Food & Drink Business) | — |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change |
|---|---|
20 Jun 2022 | Peng Shen and Zhan Wang appointed |
1 Sep 2022 | Brett Crowley (Chair) and Bing Hui Gong removed; Zhi Guo Zhang appointed COO and ED |
7–8 Sep 2022 | Bo Qiang ceased as MD (resigned as NED 25 Nov 2022); Zhan Wang appointed MD |
10 Jan 2023 | CEO Wilton Yao terminated (litigation ongoing) |
31 Jan 2023 | Sunny Jian Xin Liang appointed COO and ED |
8 Jan 2024 | Sunny Liang appointed CEO |
Nov 2024 | Zhan Wang resigned as MD and director |
Mar 2025 | Sean Li appointed ED |
3 Sep 2025 | Sunny Liang resigned as CEO and ED |
15 Sep 2025 | Sean Li appointed CEO (3-month notice by CEO under appointment terms) |
29 Oct 2025 | Zhan Wang re-appointed as NED |
Directors' Remuneration
| Item | FY2025 | FY2026 |
|---|---|---|
Aggregate directors' fees (AUD Mn) | 0.56 | 0.53 |
CEO Sunny Liang total compensation (AUD Mn) | 0.37 | — |
Related-party directors' remuneration and consulting fees, Q4 FY26 quarter only (AUD Mn) | — | 0.12 |
Major Shareholders
| Holder | Stake % | As at | Source |
|---|---|---|---|
HS Global E-Commerce (HK) Limited and Simon Lin (combined) | 31.30 | 16 Jan 2026 | 1H FY26 Interim Report |
Gold Brick Capital (Zhan Wang) | 19.99 | — | Food & Drink Business |
Superhero Securities Limited (Client A/c, nominee) | 8.00 | 30 Jun 2023 (pre-consolidation) | Market Index |
Sunny Liang (former CEO) | 0.09 | c.2025 | Simply Wall St |
Competitive Landscape
Peer Comparison FY2026
| Metric | Jatcorp | Bubs Australia |
|---|---|---|
Revenue | 38.9 | 111.9 |
Revenue growth % | 23.2 | 9.2 |
Gross margin % | 15.8 (audited basis) | 39.8 |
EBITDA | -3.4 | -1.8 |
China revenue | 8.0 (segment) | 21.4 |
Recent Developments
Comparability caveat on quarterly figures: * Quarterly revenue in Appendix 4C reports (e.g., A$12.38m in Q2 and A$12.93m in Q4) is unaudited. It may not be on the same basis as statutory revenue after TPE netting. The four quarters cannot be reconciled to the A$38.87m annual figure from the data available.



